Nectero Medical, Inc.的动态

NS Pharma has released the preliminary results of their RACER53 Phase 3 clinical trial for VILTEPSO (viltolarsen) in boys with Duchenne muscular dystrophy. The study failed to achieve its primary objective. Which was to demonstrate a significant difference in time-to-stand following VILTEPSO treatment, compared to the control group. However, there were no new safety concerns raised during this part of the study. It is not currently known how this will affect any future approval of VILTEPSO in the UK and Europe. Read more about the implications and next steps: https://lnkd.in/ed_Qp3t2

Antisense Therapy - What are the possibilities and Limitations. A good read (recently published in Nature) for detailed information on: 1. Possible treatment strategies 2. Additional aspects, such as the target tissues, intervention time points, and potential clinical benefits, which need to be considered before developing a compound. 3. Limitations #antisensetherapy #mrna #biopharma #pharmaceuticalindustry #marketaccess #newdrug #drugapproval #heor #rwe

Listen To The Presentation -on ACD440, a novel non-opioid TRPV1 antagonist analgesic against neuropathic pain The presentation is given by M?rta Segerdahl, MD, PhD, and CMO at AlzeCure Pharma Listen in: https://lnkd.in/dbTaFg6Y #alzecure #TRPV1antagonist #acd440 #neuropathicpain #painmanagement?

Preclinical data highlight potential of Avacta's pre|CISION tech & pipeline beyond AVA6000, with AVA6103 (#exatecan PDC) & AVA7100 (1st #AffDC). Delivery of highly potent payloads to TME (reduces systemic toxicities/improves therapeutic index) + potential to treat low FAP tumours. #AVCT https://lnkd.in/dxcu2fT

Thoughts on this? >> Wave rides new Phase 2 DMD data as it sets sights on accelerated approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #productmarketing

Thoughts on this? >> Wave rides new Phase 2 DMD data as it sets sights on accelerated approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

Glaukos Corporation is moving towards FDA approval for their innovative iLink corneal cross-linking therapy, Epioxa, aimed at treating keratoconus after successful Phase III trial results. This is a significant step forward for those affected by this progressive eye disease ?? The Phase III trial achieved its primary endpoint, showing a statistically significant improvement in maximum corneal curvature (Kmax) at 12 months compared with the placebo. This outcome meets the US FDA's efficacy criteria, which is a key indicator of disease progression in keratoconus trials. Glaukos plans to file for US approval by the end of the year, leveraging data from this and a previous Phase III trial to strengthen their new drug application ? This novel approach avoids the removal of the corneal epithelium, making it a significant advancement over existing treatments. With Glaukos' stock rising and a market cap standing at $7bn, it's clear that investors are optimistic about this innovation ?? #LifeSciences #Biotechnology #Keratoconus #GlaukosCorporation #RetinalDiseases #Glaucoma #CornealDisorders #StaffingPartner #ElixirAssociates

With the CELLSEARCH CTC HER2 Biomarker with Enumeration Test, healthcare providers have the ability to monitor HER status in real time, all from a simple blood draw. CTC expression of HER2 is not tied to the HER2 status of primary tumors and can present themselves at any time. By being able to monitor for positive HER2 expression on the surface of CTCs, physicians are able to open the door to targeted treatment options their patients may not have previously been candidates for. Due to the non-invasive monitoring of HER2 on CTCs may offer powerful corollary data to biopsies taken during monitoring of treatment efficacy with HER2-targeting agents, or when biopsy is difficult or contraindicated, and can be performed at any desired interval due to the ease of a blood test. https://lnkd.in/dPGqv26W Available as a lab service in the US. Available as a kit everywhere else. The CELLSEARCH? Circulating Tumor Test with HER2 Biomarker enumeration test is a validated Laboratory Developed Test within a CLIA certified laboratory, and is not cleared or approved by FDA. #HER2 #CTC #CELLSEARCH

With the CELLSEARCH CTC HER2 Biomarker with Enumeration Test, healthcare providers have the ability to monitor HER status in real time, all from a simple blood draw. CTC expression of HER2 is not tied to the HER2 status of primary tumors and can present themselves at any time. By being able to monitor for positive HER2 expression on the surface of CTCs, physicians are able to open the door to targeted treatment options their patients may not have previously been candidates for. Due to the non-invasive monitoring of HER2 on CTCs may offer powerful corollary data to biopsies taken during monitoring of treatment efficacy with HER2-targeting agents, or when biopsy is difficult or contraindicated, and can be performed at any desired interval due to the ease of a blood test. https://lnkd.in/dPGqv26W Available as a lab service in the US. Available as a kit everywhere else. The CELLSEARCH? Circulating Tumor Test with HER2 Biomarker enumeration test is a validated Laboratory Developed Test within a CLIA certified laboratory, and is not cleared or approved by FDA. #HER2 #CTC #CELLSEARCH

Unexpected cardiac side effects are the leading causes of clinical trial discontinuation and drug withdrawal. In this webinar brought to you by Lumencor, Inc., discover an automated optical scanning technique that enables high throughput drug cardiotoxicity screening. Register now: https://ow.ly/eaLm50U2HgO